From Medscape Oncology

Coverage From The

American Society of Hematology (ASH) 2018

December 01 - 05, 2018; San Diego, California

December 01 - 05, 2018 San Diego, California

ASH 2018 Choosing Wisely Champions Cut Blood RBC Transfusions, HIT testing Two researchers hailed as 'Choosing Wisely Champions' describe how they reduced blood transfusions and inappropriate testing for heparin-induced thrombocytopenia (HIT).
Medscape Medical News, December 14, 2018
ASH 2018 Reducing Inappropriate Vancomycin Use in Cancer Patients A clinician who reduced the inappropriate use of vancomycin in patients with blood cancers and neutropenic fever has been hailed as a 'Choosing Wisely Champion.'
Medscape Medical News, December 14, 2018
ASH 2018 Ibrutinib Alone for Older Patients With Untreated CLL Ibrutinib alone and ibrutinib with rituximab were both superior to the bendamustine–rituximab combination for older patients with chronic lymphocytic leukemia (CLL).
Medscape Medical News, December 3, 2018

Meeting Highlights At A Glance

Top News From ASH 2018: Slideshow Hot topics include practice change data on chronic lymphocytic leukemia, validation of the durability of CAR T cells, and a new standard of care in myeloma.

Conference News

ASH 2018 Choosing Wisely Champions Cut Blood RBC Transfusions, HIT testing
Medscape Medical News, December 14, 2018
ASH 2018 Reducing Inappropriate Vancomycin Use in Cancer Patients
Medscape Medical News, December 14, 2018
ASH 2018 New Sickle Cell Test Can Transform Screening
Medscape Medical News, December 10, 2018
ASH 2018 Daratumumab Plus Len/Dex: New Standard of Care in Myeloma?
Medscape Medical News, December 6, 2018
ASH 2018 Why Some CLL Patients Stop Responding to Venetoclax
Medscape Medical News, December 5, 2018
ASH 2018 Ibrutinib and Rituximab for Untreated CLL: 'Practice Changing'
Medscape Medical News, December 4, 2018
ASH 2018 'Marginal Benefit' With Rivaroxaban in Cancer Patients
Medscape Medical News, December 4, 2018

ASH 2018 Ibrutinib Alone for Older Patients With Untreated CLL
Medscape Medical News, December 3, 2018
ASH 2018 Microbiome Before HSCT Predictive of Survival and Complications
Medscape Medical News, December 3, 2018
ASH 2018 Model Improves Predictions of Myelodysplastic Syndrome Prognosis
Medscape Medical News, December 3, 2018
ASH 2018 Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia
Medscape Medical News, December 2, 2018
ASH 2018 Four Cycles of CHOP Instead of Six for Favorable DLBCL
Medscape Medical News, December 2, 2018
ASH 2018 CAR T Cells: 'Validation That They Keep Living and Keep Working'
Medscape Medical News, December 2, 2018
ASH 2018 What's Hot at This Year's ASH Meeting?
Medscape Medical News, November 23, 2018

Popular News from ASH 2017

Top News From ASH 2017: Slideshow Hot topics include moving to newer oral anticoagulants for cancer patients with VTE, plus practice-changing results in chronic lymphocytic leukemia, multiple myeloma, and Hodgkin's lymphoma.
Medscape Medical News, Dec 22, 2017
Oral Agents for Cancer-Related VTE: 'New Standard of Care' The oral agent rivaroxaban was as effective as subcutaneous dalteparin in controlling VTE in patients with cancer but was associated with a higher rate of bleeding.
Medscape Medical News, Dec 18, 2017
Mastocytosis Becomes a 'Disease You Don't Want to Miss' A novel drug designed specifically to target a mutation found in 90% of cases shows marked activity, and has already sparked an increase in interest in this disease.
Medscape Medical News, Dec 10, 2017

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Oncology Insights

CAR T Cell Therapy: 'It's the Real World Now'
Caron A. Jacobson, MD, MMSc; Marcela V. Maus, MD, PhD; David Miklos, MD, PhD
ASH 2018: 'Amazing Developments' in AML Treatment
Jorge E. Cortes, MD
National Cancer Institute Director Promises New Directions to Accelerate Route to Cure
Theodore Bosworth
Four Major Developments in Multiple Myeloma: ASH 2018
Joseph Mikhael, MD, MEd, FRCPC
Venetoclax Shows Benefits Across a Range of Hematologic Cancers
Ann S. LaCasce, MD, MMSc; Jennifer L. Crombie, MD

Previous Coverage